Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One.

A Masurekar; C Parker; M Shanyinde; A Moorman; J Hancock; R Sutton; P Ancliff; M Morgan; N Goulden; C Fraser; P Hoogerbrugge; T Revesz; P Darbyshire; S Krishnan; S Love; V. Saha

doi:10.1371/journal.pone.0108107

Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One.

A Masurekar, C Parker, M Shanyinde, A Moorman, J Hancock, R Sutton, P Ancliff, M Morgan, N Goulden, C Fraser, P Hoogerbrugge, T Revesz, P Darbyshire, S Krishnan, S Love, V. Saha

Research output: Contribution to journal › Article › peer-review

Abstract

The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age

Original language	English
Pages (from-to)	1-13
Number of pages	12
Journal	P L o S One
Volume	9
Issue number	10
DOIs	https://doi.org/10.1371/journal.pone.0108107
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0108107

Cite this

Masurekar, A., Parker, C., Shanyinde, M., Moorman, A., Hancock, J., Sutton, R., Ancliff, P., Morgan, M., Goulden, N., Fraser, C., Hoogerbrugge, P., Revesz, T., Darbyshire, P., Krishnan, S., Love, S., & Saha, V. (2014). Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One. P L o S One, 9(10), 1-13. https://doi.org/10.1371/journal.pone.0108107

@article{0361111520754cf6a084f14419b61ce3,

title = "Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One.",

abstract = "The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age",

author = "A Masurekar and C Parker and M Shanyinde and A Moorman and J Hancock and R Sutton and P Ancliff and M Morgan and N Goulden and C Fraser and P Hoogerbrugge and T Revesz and P Darbyshire and S Krishnan and S Love and V. Saha",

year = "2014",

doi = "10.1371/journal.pone.0108107",

language = "English",

volume = "9",

pages = "1--13",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

Masurekar, A, Parker, C, Shanyinde, M, Moorman, A, Hancock, J, Sutton, R, Ancliff, P, Morgan, M, Goulden, N, Fraser, C, Hoogerbrugge, P, Revesz, T, Darbyshire, P, Krishnan, S, Love, S & Saha, V 2014, 'Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One.', P L o S One, vol. 9, no. 10, pp. 1-13. https://doi.org/10.1371/journal.pone.0108107

TY - JOUR

T1 - Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One.

AU - Masurekar, A

AU - Parker, C

AU - Shanyinde, M

AU - Moorman, A

AU - Hancock, J

AU - Sutton, R

AU - Ancliff, P

AU - Morgan, M

AU - Goulden, N

AU - Fraser, C

AU - Hoogerbrugge, P

AU - Revesz, T

AU - Darbyshire, P

AU - Krishnan, S

AU - Love, S

AU - Saha, V.

PY - 2014

Y1 - 2014

N2 - The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age

AB - The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age

U2 - 10.1371/journal.pone.0108107

DO - 10.1371/journal.pone.0108107

M3 - Article

SN - 1932-6203

VL - 9

SP - 1

EP - 13

JO - P L o S One

JF - P L o S One

IS - 10

ER -

Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLOS One.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this